inmagene-biopharmaceuticals-secures-21-million-in-series-b-funding
By Akshay Kedari  Date: 2020-11-09

inmagene-biopharmaceuticals-secures-21-million-in-series-b-funding

Inmagene Biopharmaceuticals, a Chinese pharmaceutical company, has recently revealed that it has logged US$21 million from its Series B funding round which was led by Vertex Ventures China. Reportedly, the funding saw co-investment from investors like Kunlun Capital, Panacea Venture, and SCVC.

As per sources, the capital will be utilized for research and development, product in-licensing activities and global clinical trials. As of this date, Inmagene has managed to raise more than $40 million from fundraising. The company is a prominent drug developer that specializes in immunology-related therapeutic regions.

Inmagene’s management team is deeply rooted in China and has a strong global experience. Its pipeline is strengthened by two prospects- the first being its in-licenses clinical-stage foreign therapeutics that suits China, while the second being its strategic relations with global players along with whom it conducts wide-scale multi-center clinical trials.

It is worth noting that Inmagene leverages China's cost-efficient resources to create best-in-class drugs at an affordable price point. Moreover, it has commenced four new innovative programs for validated drug targets.

Speaking on the move, Dr. Jonathan Wang, CEO and Chairman, Inmagene, said that the company is grateful to Panacea, Vertex, SCVC and Kunlun along with other investors for providing strong support. This financing will help the firm strengthen its leading position in China’s immunology drug development space.

Mr. Tay Choon Chong, Managing Partner, Vertex Ventures China, commented that the organization is delighted to be a part of Inmagene's Series B funding round as its lead investor. The development of immunology-related therapeutics still remains as a 'blue ocean' in China.

Mr. Chong added that Inmagene has made some early breakthroughs in the field of immunology and has managed to develop a strong R&D pipeline. Vertex believes that with a broad global vision and robust innovative capabilities, Inmagene has the potential to develop more competitive products at a global scale to satisfy patients' needs.

Source Credit: https://www.pharmiweb.com/press-release/2020-11-09/inmagene-biopharmaceuticals-closed-21-million-series-b-financing-making-the-total-raised-to-date-o

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Lab-grown, no-kill meat to be put on sale in Singapore for first time
Lab-grown, no-kill meat to be put on sale in Singapore for first time
By Akshay Kedari

Cultured, lab-grown meat, produced inside bioreactors without slaughtering any animals, has reportedly been approved to go on sale for the first time by regulatory authorities in Singapore. The new development is being hailed as a momentous, landmark...

Chancellor Rishi Sunak pledges £100bn to transform UK’s infrastructure
Chancellor Rishi Sunak pledges £100bn to transform UK’s infrastructure
By Akshay Kedari

As per the statement of chancellor Rishi Sunak, Britain’s first nationwide infrastructure plan would provide a “once in a lifetime investment” of approximately £100 billion to drive the nation’s recovery from the COVID-1...

Telus Communications selects Nokia to deliver 5G services in Canada
Telus Communications selects Nokia to deliver 5G services in Canada
By Akshay Kedari

According to reliable sources, Nokia Corporation has reportedly been selected by Canada-based Telus Communications Inc. to provide 5G services in Canada. The Finnish multinational technology giant will reportedly support the Canadian mobile service o...

TBI, Oracle to jointly launch cloud-based vaccine management system
TBI, Oracle to jointly launch cloud-based vaccine management system
By Akshay Kedari

Tony Blair Institute (TBI) and Oracle have recently introduced cloud technology to Africa for effective management of public health programs in the region. As per credible sources, initially, Ghana, Sierra Leone and Rwanda will use the new Oracl...

Minerva Bunkering unveils ADP for better clarity in bunker deliveries
Minerva Bunkering unveils ADP for better clarity in bunker deliveries
By Akshay Kedari

Swiss supplier of marine fuels Minerva Bunkering has reportedly introduced an innovative solution called Advanced Delivery Platform (ADP) in a bid to increase efficiency and transparency during bunkering operations. According to reliable sources, Min...